Evaluation of the Coloplast Titan® IPP for Maintaining Penile Length While Treating Erectile Dysfunction (ED)
Launched by COLOPLAST A/S · Aug 8, 2008
Trial Information
Current as of June 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Has an estimated life expectancy of more than 5 years
- • Has been diagnosed with erectile dysfunction
- • Is willing to have the Titan IPP implanted
- • Is able and willing to complete all follow-up visits and procedures indicated in this protocol
- • Has been informed of the nature of the study and agrees to its provisions and - Has provided written informed consent as approved by the Institutional Review board of the respective site
- Exclusion Criteria:
- • Participant has had a previous penile prosthesis or prior penile enlargement surgeries
- • Participant has a compromised immune system
- • Participant has had a myocardial infarction or coronary artery stent placement within 2 months prior to treatment
- • Participant does not have manual dexterity or mental ability to operate the pump
- • Participant has an active urogenital infection or active skin infection in region of surgery
- • Participant is diagnosed with fibrotic disease, such as priapism or Peyronie's disease
- • Participant is diagnosed with Chordee
- • Participant has neuropathy
- • Participant has a serious bleeding disorder or coagulopathy
About Coloplast A/S
Coloplast A/S is a leading global medical device company headquartered in Denmark, specializing in products and services for individuals with intimate healthcare needs. With a strong commitment to innovation, Coloplast develops solutions in areas such as ostomy care, urology, and wound care. The company prioritizes patient-centered design, combining advanced technology with user-friendly applications to enhance quality of life for patients. Coloplast A/S actively conducts clinical trials to validate the safety and efficacy of its products, ensuring they meet the highest standards of care and contribute to improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Shreveport, Louisiana, United States
Tampa, Florida, United States
Patients applied
Trial Officials
Gerard Henry, MD
Principal Investigator
Regional Urology, LLC
Rafael Carrion, MD
Principal Investigator
JAames A Haley VA
Run Wang, MD
Principal Investigator
University of Texas
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials